HSDT
Solana Company
NASDAQ · Healthcare · Medical - Devices · US
$2.24
−4.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.1M | 6.0M | 520.0K | 644.0K | 787.0K |
| Cost of Revenue | 540.0K | 500.0K | 582.0K | 583.0K | 463.0K |
| Gross Profit | 11.5M | 5.5M | (62.0K) | 61.0K | 324.0K |
| Operating Expenses | |||||
| R&D Expense | 1.7M | 3.5M | 3.7M | 2.9M | 4.3M |
| SG&A Expense | 34.0M | 23.1M | 10.1M | 9.3M | 10.6M |
| General & Admin Expense | 16.3M | — | 9.5M | — | — |
| Selling & Marketing Expense | — | — | 651.0K | — | — |
| Other Expenses | — | — | 64.0K | 276.0K | 938.0K |
| Total Operating Expenses | 35.7M | 26.6M | 13.8M | 12.5M | 15.8M |
| Cost and Expenses | 36.3M | 27.1M | 14.4M | 13.1M | 16.3M |
| Operating Income (EBIT) | (24.2M) | (21.1M) | (13.9M) | (12.4M) | (15.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 257.0K | — |
| Interest Expense | 68.0K | 635.0K | 17.0K | — | 834.0K |
| Net Interest Income | (68.0K) | (635.0K) | (17.0K) | 257.0K | (834.0K) |
| Other Non-Op Income/Expense | (133.1M) | (19.8M) | 2.2M | 3.6M | 1.4M |
| Non-Operating Income (excl Interest) | 111.5M | 19.1M | (40.0K) | (159.0K) | (757.0K) |
| EBT (Pre-Tax Income) | (157.3M) | (40.9M) | (11.7M) | (8.8M) | (14.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (157.3M) | (40.9M) | (11.7M) | (8.8M) | (14.1M) |
| Earnings from Cont. Ops | (157.3M) | (40.9M) | (11.7M) | (8.8M) | (14.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (157.3M) | (40.9M) | (11.7M) | (8.8M) | (14.1M) |
| Per Share | |||||
| Basic EPS | ($30.32) | ($1.85) | ($4.33) | ($7.28) | ($26.06) |
| Diluted EPS | ($30.32) | ($1.85) | ($4.33) | ($7.28) | ($26.06) |
| Revenue Per Share | $0.15 | $0.27 | $0.19 | $0.53 | $1.46 |
| Shares | |||||
| Basic Shares Outstanding | 78.3M | 22.0M | 2.7M | 1.2M | 539886 |
| Diluted Shares Outstanding | 78.3M | 22.0M | 2.7M | 1.2M | 539886 |
| Profitability Metrics | |||||
| EBITDA | (135.0M) | (39.6M) | (13.8M) | (12.1M) | (14.5M) |
| D&A | 663.0K | 680.0K | 60.0K | 162.0K | 255.0K |
| EBIT | (135.7M) | (40.3M) | (13.9M) | (12.3M) | (14.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026